Compare SGRY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | NBTX |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2015 | 2018 |
| Metric | SGRY | NBTX |
|---|---|---|
| Price | $15.49 | $38.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $22.25 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.4M | 112.4K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,145,438,000.00 | N/A |
| Revenue This Year | $5.09 | $58.17 |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.41 | $6.09 |
| 52 Week High | $24.10 | $57.14 |
| Indicator | SGRY | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 50.06 |
| Support Level | $15.06 | $30.15 |
| Resistance Level | $16.44 | $42.40 |
| Average True Range (ATR) | 0.87 | 2.32 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 38.90 | 50.34 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.